Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a ...

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early diagn ...

Regulatory clearance positions secukinumab as the sole IL‑17A–targeting option for pediatric HS, expanding therapeutic choice beyond historically limited adolescent interventions. IL‑17A blockade is ...

After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of its ...

Monoclonal antibodies are a type of biologic medication that can treat moderate to severe inflammatory bowel disease (IBD) by targeting specific inflammatory processes in your body. Your doctor might ...

UCB said it’s the first time an approved biologic demonstrated superiority over an IL-23 blocker in psoriatic arthritis. Yet analysts aren’t sure how commercially impactful the results will be.

Ultomiris is a brand-name biologic medication prescribed for certain rare autoimmune disorders. Dosing of Ultomiris is done via intravenous (IV) infusions administered by a healthcare professional.

Hilary Hodge suffers from severe allergic asthma. But in 2012, she saw hope in biologic medication. There was one catch: She was living in the United States at the time, and biologics would cost her ...

To learn more about our editorial approach, explore The Direct Message methodology. Gerald Pace, 71, takes his blood pressure pill every morning at the same time — right after he pours his second cup ...

Aging means “becoming a target” of the industry, one expert said. After decades of debate, politicians of all stripes are proposing bans. By Paula Span Tamar Abrams had a lousy couple of years in 2022 ...

Some Americans are moving abroad to access more affordable and comprehensive health care. Nearly half of American adults worry about affording medication or health-related expenses. Other factors for ...